// App-Quantinova.ai

P63.05 : Treatment Pattern in Small Cell Lung Cancer: A Real-world Observational Study in the Era of Immune Checkpoint Inhibitors

Researchers

Presenter

  • K. Zu

Principal Investigators

  • A. Arunachalam

  • S. Macdonald

  • Y. Wang

  • K. Wells

Medical Centers

  • Iqvia, Plymouth Meeting/PA/US

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Estrogen receptor alpha

  • Cytotoxic T-lymphocyte-associated protein 4

  • Tumor protein p63

Drug/Treatment

  • Atezolizumab

  • Carboplatin

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved